Claims for Patent: 10,695,339

Summary for Patent: 10,695,339

Title:	Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation
Abstract:	The present disclosure provides a method of treating a central nervous system disorder in a patient in need thereof. The method comprises orally administering between 75 mg and 300 mg xanomeline salt and between 20 mg and 200 mg trospium chloride to the patient during a 24-hour period, the central nervous system disorder being selected from schizophrenia, Alzheimer's disease, Huntington's disease, Parkinson's disease, and Lewy Body dementia, wherein use of the trospium chloride alleviates a side effect associated with use of the xanomeline salt.
Inventor(s):	Eric Elenko, Philip E. Murray, III, Andrew C. Miller
Assignee:	Puretech Health LLC , Puretech Management Inc
Application Number:	US16/444,206
Patent Claims:	1. A method of treating a central nervous system disorder in a patient in need thereof, the method comprising orally administering between 75 mg and 300 mg xanomeline salt and between 20 mg and 200 mg trospium chloride to the patient during a 24-hour period, the central nervous system disorder being selected from schizophrenia, Alzheimer's disease, Huntington's disease, Parkinson's disease, and Lewy Body dementia, wherein use of the trospium chloride alleviates a side effect associated with use of the xanomeline salt. 2. The method of claim 1, wherein the central nervous system disorder is schizophrenia. 3. The method of claim 1, wherein the central nervous system disorder is Alzheimer's disease. 4. The method of claim 1, wherein the central nervous system disorder is Huntington's disease. 5. The method of claim 1, wherein the central nervous system disorder is Parkinson's disease. 6. The method of claim 1, wherein the central nervous system disorder is Lewy Body dementia. 7. The method of claim 1, wherein 225 mg of xanomeline salt and between 20 mg and 60 mg of trospium chloride are administered to the patient during the 24-hour period. 8. The method of claim 1, wherein the xanomeline salt and the trospium chloride are in the same dosage vehicle. 9. The method of claim 1, wherein the xanomeline salt and the trospium chloride are in different dosage vehicles. 10. The method of claim 1, wherein xanomeline salt is administered to the patient three times during the 24-hour period. 11. The method of claim 1, wherein trospium chloride is administered to the patient two times during the 24-hour period. 12. The method of claim 1, wherein between 20 mg and 60 mg of trospium chloride is administered to the patient during the 24-hour period. 13. The method of claim 1, wherein between 60 and 200 mg trospium chloride is administered to the patient during the 24-hour period. 14. The method of claim 1, wherein between 75 mg and 225 mg xanomeline salt and between 20 mg and 60 mg trospium chloride are administered to the patient during the 24-hour period. 15. The method of claim 1, wherein 300 mg xanomeline salt and between 60 mg and 200 mg trospium chloride are administered to the patient during a 24-hour period. 16. The method of claim 1, wherein the xanomeline salt is the salt of tartaric acid.